Roche’s new dual-target HIV-1 test approved in Europe
An intriguing article published in the December 2008 online issue of Journal of Neurosurgery: Pediatrics may come as quite a surprise to parents, especially those with little girls. The article, “Radiolucent hair accessories causing depressed skull fracture following blunt cranial trauma” discusses the cases of a 4-year-old and 2 ½-year-old treated for blunt head trauma.
Full Post: Neurological health risk in children with blunt head injuries: fashion hair beads
Roche announced today that its innovative dual-target HIV-1 test has received CE Mark certification, allowing it to be sold for clinical use in the European Union. The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 utilizes a unique design to simultaneously amplify and detect two separate regions of the HIV-1 genome.
This approach provides reliable test results even when mutations are present. The test uses Roche’s proprietary fully automated real-time PCR technology to quantify the amount of HIV-1 RNA in a patient’s blood.
“HIV mutations are a serious problem. Because it is impossible to predict when these mutations will occur, we have designed this test to detect all HIV-1 (Group M and O) strains,” said Daniel O’Day, President and CEO of Roche Molecular Diagnostics. “This innovative fully-automated solution will provide reliable results for laboratories and physicians to more confidently and efficiently treat HIV-1 patients undergoing therapy.”
It is critical for viral load monitoring tests to be able to quantify very low and high levels of virus, an indicator of the need for more or less aggressive treatment. The test is highly sensitive and can detect the World Health Organization HIV-1 RNA Standard in EDTA plasma as low as 20 copies per milliliter of patient sample. The test can also accurately quantify the amount of HIV in a patient sample up to 10 million copies/mL representing a broader dynamic range than previous generation tests.
The COBAS AmpliPrep / COBAS TaqMan HIV Test, v2.0 is the first dual-target test to be offered on the COBAS AmpliPrep / COBAS TaqMan System. The test is designed for use on the fully automated, real-time PCR platform, providing sample-in/results-out capability. The COBAS AmpliPrep / COBAS TaqMan System is flexible and customizable to meet the space and workflow needs of any laboratory. In 2005, Roche received CE Mark certification for the full viral load monitoring menu (HIV-1, HBV, and HCV) on the system.
According to estimates by the World Health Organization (WHO) and UNAIDS, 33.2 million people were living with HIV at the end of 2007. That same year, some 2.5 million people became newly infected, and 2.1 million died of AIDS, including 330,000 children.
The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human immune system, destroying or impairing their function. In the early stages of infection, the person has no symptoms. Within 10-15 years an HIV infection will develop into acquired immunodeficiency syndrome (AIDS); antiretroviral drugs can slow down this process even further.
HIV is transmitted through unprotected sexual intercourse (anal or vaginal), transfusion of contaminated blood, sharing of contaminated needles, and between a mother and her infant during pregnancy, childbirth and breastfeeding.
The ability of HIV to mutate itself in the presence of antiretroviral drugs can lead to treatment failure, increased direct and indirect health costs associated with the need to start more costly second-line treatment for patients, the spread of resistant strains of HIV and the need to develop new anti-HIV drugs.
Roche and Memory Pharmaceuticals has announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million. Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS)
Full Post: Roche to acquire Memory Pharmaceuticals
Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12×135K format for analysis of DNA copy number variation. NimbleGen CGH 12×135K arrays allow simultaneous analysis of 12 independent sample pairs on a single microarray slide, each with 135,000 empirically tested long oligonucleotide probes. This new array format will enable rapid and
Full Post: Roche NimbleGen launches microarrays for analysis of DNA copy number variation
Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer’s disease and
Full Post: Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists
A new and simple urine test can detect polyomavirus nephropathy, a relatively new and serious complication that affects up to 9% of kidney transplant recipients, according to a study appearing in the February 2009 issue of the Journal of the American Society Nephrology (JASN). The advance could lead to better diagnosis and treatment of patients
Full Post: New and simple urine test detects common cause of kidney transplant failure
If doctors were able to conduct efficient genetic analysis at the point of care, using inexpensive, portable equipment, it would revolutionise disease detection and treatment. European researchers are close to enabling this revolution. Today, anybody getting tests done in a GP’s surgery or hospital outpatients will usually have to wait several days before getting any
Full Post: Lab on a microfluidic chip for the GP’s surgery